Fresenius SE: Berenberg cuts target price; keeps 'buy'
(CercleFinance.com) - Berenberg cut its target price for the Fresenius SE share from 74.
8 euros to 72.1 euros, due to two factors, but reiterated its "buy" rating on the stock.
According to the broker, in 2020 Fresenius SE's share price will most likely be dictated by just two fundamental factors - private hospital operator Helios in Germany and the infusion unit Kabi in North America.
"We think that fears are easing over Helios Germany and expect a gradual return to form for Kabi North America," Berenberg said.
The broker points out however that its new target price still suggests "healthy" upside potential of 41%.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
8 euros to 72.1 euros, due to two factors, but reiterated its "buy" rating on the stock.
According to the broker, in 2020 Fresenius SE's share price will most likely be dictated by just two fundamental factors - private hospital operator Helios in Germany and the infusion unit Kabi in North America.
"We think that fears are easing over Helios Germany and expect a gradual return to form for Kabi North America," Berenberg said.
The broker points out however that its new target price still suggests "healthy" upside potential of 41%.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.